Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Solid Tumor”

177 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 177 results

Testing effectiveness (Phase 2)Looking for participantsNCT05673928
What this trial is testing

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Who this might be right for
Metastatic Solid TumorBrain Metastases
M.D. Anderson Cancer Center 30
Early research (Phase 1)Looking for participantsNCT05461768
What this trial is testing

BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 348
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Early research (Phase 1)Study completedNCT04257110
What this trial is testing

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Who this might be right for
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd 117
Early research (Phase 1)Study completedNCT01409343
What this trial is testing

TrasGEX™: Phase 1 Study in Cancer Patients

Who this might be right for
Solid Tumors
Glycotope GmbH 37
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Testing effectiveness (Phase 2)UnknownNCT05338957
What this trial is testing

MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Who this might be right for
Advanced Malignant Solid Tumors
Shanghai Miracogen Inc. 30
Very early researchLooking for participantsNCT07009184
What this trial is testing

TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.

Who this might be right for
HER2 Positive Solid Tumor
Radboud University Medical Center 19
Early research (Phase 1)Looking for participantsNCT06500052
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+2 more
Sichuan Baili Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)UnknownNCT02396108
What this trial is testing

Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
National University Hospital, Singapore 55
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT04215159
What this trial is testing

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Who this might be right for
HER-2 Protein OverexpressionHER-2 Gene Amplification
Jin-Hee Ahn 42
Very early researchLooking for participantsNCT04684459
What this trial is testing

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

Who this might be right for
Peritoneal Carcinoma MetastaticPleural Effusion, MalignantHER2 Positive Malignancies
Sichuan University 18
Early research (Phase 1)Looking for participantsNCT03842085
What this trial is testing

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

Who this might be right for
HER2-positive Recurrent or Metastatic Malignant Solid Tumor
Beijing Mabworks Biotech Co., Ltd. 34
Not applicableLooking for participantsNCT07124000
What this trial is testing

DESTINY-PANTUMOUR04

Who this might be right for
Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more
AstraZeneca 100
Testing effectiveness (Phase 2)WithdrawnNCT04757090
What this trial is testing

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Who this might be right for
HER2-positive Solid TumorHER-2 Positive Cancer
Washington University School of Medicine
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Looking for participantsNCT06503783
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 20
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Ended earlyNCT02829372
What this trial is testing

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

Who this might be right for
HER2 Expressing Solid Tumours
Ichnos Sciences SA 36
Next Page